NCT03589547: 358

Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III Non-Small Cell Lung

Completed Phase 2 Last updated 2 April 2026

What this trial tests

Phase 2 trial testing Durvalumab in Stage III Non-small-cell Lung Cancer in 11 participants. Completed in 18 February 2026.

Timeline

13 May 2019

Primary endpoint
31 January 2024

18 February 2026

Quick facts

Lead sponsor	Brown University
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	11
Start date	13 May 2019
Primary completion	31 January 2024
Estimated completion	18 February 2026
Sites	2 locations across United States

Drugs / interventions tested

• Durvalumab — full drug profile →
• SBRT — full drug profile →

Conditions studied

• Stage III Non-small-cell Lung Cancer — all drugs for Stage III Non-small-cell Lung Cancer →

Sponsor

Brown University

Who can join

18 and older, any sex, with Stage III Non-small-cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Durvalumab is a drug that stimulates the immune system to fight lung cancer. Durvalumab is FDA approved to treat lung cancer. Stereotactic body radiation therapy (SBRT) is a newer radiation treatment that gives fewer, but higher doses of radiation than standard radiation.

With SBRT, radiation is focused toward the cancer and away from normal surrounding lung tissue. It is possible that when cancer cells are damaged by SBRT Durvalumab may be more effective in activating the immune system. SBRT is a standard FDA approved treatment for early stage (stage 1) lung cancer and is investigational in patients such as yourself with stage 3 lung cancer. The combination of Durvalumab and SBRT is investigational. This study will investigate the effects, good and bad, of the combination of Durvalumab and SBRT.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy.
   Ai L, Chen J, Yan H, He Q, et al · · 2020 · cited 149× · PMID 32982171 · DOI 10.2147/dddt.s267433
2. SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges.
   Chen Y, Gao M, Huang Z, Yu J, et al · · 2020 · cited 125× · PMID 32723363 · DOI 10.1186/s13045-020-00940-z
3. Is the Combination of Immunotherapy and Radiotherapy in Non-small Cell Lung Cancer a Feasible and Effective Approach?
   Spaas M, Lievens Y. · · 2019 · cited 31× · PMID 31788476 · DOI 10.3389/fmed.2019.00244
4. International consensus on radiotherapy in metastatic non-small cell lung cancer.
   Zhu Z, Ni J, Cai X, Su S, et al · · 2022 · cited 27× · PMID 36248338 · DOI 10.21037/tlcr-22-644
5. Immunoradiotherapy as An Effective Therapeutic Strategy in Lung Cancer: From Palliative Care to Curative Intent.
   Chicas-Sett R, Zafra-Martin J, Morales-Orue I, Castilla-Martinez J, et al · · 2020 · cited 27× · PMID 32764371 · DOI 10.3390/cancers12082178
6. Radiotherapy for non-small cell lung cancer in the immunotherapy era: the opportunity and challenge-a narrative review.
   Xia WY, Feng W, Zhang CC, Shen YJ, et al · · 2020 · cited 25× · PMID 33209631 · DOI 10.21037/tlcr-20-827
7. Radiotherapy as a New Player in Immuno-Oncology.
   Wang SJ, Haffty B. · · 2018 · cited 19× · PMID 30558196 · DOI 10.3390/cancers10120515
8. New developments in locally advanced nonsmall cell lung cancer.
   Huber RM, Kauffmann-Guerrero D, Hoffmann H, Flentje M. · · 2021 · cited 12× · PMID 33952600 · DOI 10.1183/16000617.0227-2020